GlassScriptPhysician profile
Marc Antony Stezzi
NPI 1093397879
$1,654.76
in general payments reported to CMS, 2019-2025
21 companies · $976 in 2025
The $976 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $125 · 2023: $219 · 2024: $218 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $321.52 | 2024-2025 | Evenity, Repatha, Tepezza |
| Astrazeneca Pharmaceuticals LP | $223.75 | 2021-2022 | |
| Abbott Laboratories | $153.57 | 2025 | Freestyle Libre 3 |
| Amryt Pharma Holdings LTD | $121.60 | 2023 | Mycapssa |
| Amphastar Pharmaceuticals, INC. | $93.41 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $91.76 | 2025 | Strensiq |
| Corcept Therapeutics | $91.05 | 2023-2025 | Korlym |
| Abbvie INC. | $87.47 | 2024-2025 | |
| Novo Nordisk INC | $80.95 | 2024-2025 | |
| Antares Pharma, INC. | $74.05 | 2023 | Nocdurna, Tlando, Xyosted |
| Lilly USA, LLC | $71.95 | 2025 | Mounjaro, Jardiance |
| Neurocrine Biosciences, INC. | $55.94 | 2025 | |
| Cequr Corporation | $31.18 | 2025 | Cequr Simplicity |
| Averitas Pharma INC. | $24.76 | 2025 | Qutenza |
| Glaxosmithkline, LLC. | $22.87 | 2025 | Shingrix, Arexvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $21.63 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $19.97 | 2024 | |
| Ascendis Pharma Endocrinology INC | $18.78 | 2025 | Yorvipath |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.47 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $16.91 | 2025 | Imcivree |
| Tolmar, INC. | $14.17 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Stezzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.